COPD

XGBoost displayed a high rate of accuracy, sensitivity, and precision, indicating its effectiveness at highlighting depressive symptoms before diagnosis.

A variety of influences and potential confounders exist to explain the increasing rates of impairment concordant with chronic obstructive pulmonary disease.

Virtual pulmonary rehabilitation enhances access and improves outcomes for COPD patients, demonstrating safety and effectiveness in individualized care.

The month in review spotlights new data for COPD and bronchiectasis, as well as new research and conversations around smoking.

Mepolizumab significantly reduces COPD exacerbations in patients with eosinophilic phenotype, offering new hope for improved management and patient outcomes.

The 25-mg brensocatib group showed statistically significant changes in FEV1 decline as well as pulmonary exacerbations.

Participants in the cytisinicline group also had a significantly greater reduction in smoking urges.

In this summary, we highlight the latest issue of our pulmonology research quarterly newsletter powered by the American Lung Association Research Institute.

Peter Miller, MD, PhD, from Massachusetts General Hospital and Harvard Medical School, is working to further uncover the role of clonal hematopoeisis in COPD.

Acute respiratory infection caused by RSV results in a nearly 3-fold increase in mortality, particularly in those with underlying respiratory conditions.

Our Q1 2025 recap for pulmonology spotlights 5 regulatory updates, 5 key trial announcements, and top expert perspectives in pulmonology care. Read now:

This March 2025 month in review covers key pulmonology updates, including new findings on pulmonary function tests and expert insights from the AAAAI/WAO Joint Congress.

By year 5, COPD exacerbations occurred in 81.3% of the PPV23 group and 23.6% of the PCV13 group.

This February 2025 month in review covers key pulmonology updates, including FDA reviews for brensocatib and PRGN-2012, dupilumab’s COPD data, and wildfire air quality risks.

Panelists discuss how individualized chronic obstructive pulmonary disease (COPD) maintenance therapy considers symptom severity, exacerbation risk, and eosinophil levels. Dupilumab and ensifentrine require adherence to prescribed dosing for efficacy and safety.